Thus, optimal targeting of HER2-positive breast cancers with a radioiodinated trastuzumab conjugate requires an acylation agent that is both residualizing and resistant to dehalogenation, to achieve high radioactivity concentrations in tumors. This evidence concerns the gene ERBB2 and breast carcinoma.